The new method of creating superantibodies is based on the use of an autophilic peptide that is crosslinked to antibodies using Immpheron's proprietary technology. Creating an autophilic superantibody increased the targeting of the antibodies and the other biological effects such as induction of apoptosis. A patent has been filed by Heinz Kohler for Immpheron to protect the method of affinity-crosslinking biologically active peptides to antibodies. The US patent office has recently allowed 17 claims of this invention. Immpheron's mission is to fully utilize the potential of antibodies to fight cancer .
Antibodies are an essential part of the immune system, the other being killer cells.
Antibodies are much better suited than T killer cells to be used as drugs because they are basically chemicals which can be produced by pharmaceutical plants. As chemical molecules, antibodies can be chemically modified as well as manufactured as recombinant proteins. Therefore, cell therapy will always remain an expensive specialized procedure similar to bone marrow transplantation. Immpheron's novel and unique technology of using antibodies takes advantage of their natural ability to find targets and to function as a vehicle to deliver diagnostic and therapeutic compounds. This antibody property has been recognized long ago and modern molecular biology methods have successfully exploited antibodies.